Guillain-Barré Syndrome After a SARS-CoV-2 Vaccine

• Published in: Cureus 2024, Vol.16 (4), p.e57705-e57705
• Main Authors: Oliveira, Ana M, Varela Ramos, Patrícia, Durão-Carvalho, Gonçalo, Almeida, Vânia, Gonçalves Pereira, João
• Format: Report
• Language: English
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.57705

The worldwide mass vaccination campaign against COVID-19 has been the largest one ever undertaken. Although the short-term safety profile of the different vaccines has been well established, neuroinflammatory complications have been described, including rare cases of acute demyelinating inflammatory polyneuropathy. We report a 63-year-old man who presented to the emergency department with proximal muscle weakness and paresthesia. He had received the first dose of the AZD1222 SARS-CoV-2 vaccine (Oxford, AstraZeneca) two weeks before presentation. The diagnosis of Guillain-Barré syndrome (GBS) was confirmed by clinical features, cerebrospinal fluid analysis, and electromyography. On the second hospital day, progression to flaccid tetraplegia, cranial nerve involvement, and respiratory failure, requiring invasive mechanical ventilation, were noted, and he was admitted to the intensive care unit. Despite the prompt diagnosis and immunosuppressive treatment initiation, the patient was left with severe disability. Although the COVID-19 vaccination was generally safe and socially beneficial, individual adverse reactions, including neuroinflammatory severe complications, may occur.